Drug development takes a great deal of time, money and effort. While future profits play a big factor in which diseases gets prioritized, advocacy and research incentives can also tilt the scale.
Warmer ocean waters are fueling the spread of the bacteria Vibrio vulnificus. Infections can lead to a rare but fatal condition called necrotizing fasciitis.
Sarah McLean, Swinburne University of Technology et Enzo Palombo, Swinburne University of Technology
Animals, including the ones that live in our homes, can carry all kinds of illnesses. Most of the time it’s not a problem, but here’s what you should do to avoid getting sick.
Spinal muscular atrophy, a disease the author of the article suffers, is one of the genetic diseases with the highest associated mortality. It is also the most expensive to cure.
Sildenafil — better known as Viagra — may be helpful in treating lung diseases like pulmonary arterial hypertension and idiopathic pulmonary fibrosis, for which there are few effective treatments.
Deciphering the biological pathways behind rare genetic diseases often involves assembling a team of specialists to work closely with the family members of those affected.
Tay-Sachs is a rare and fatal neurodegerative disorder that most commonly affects children. Researchers have developed the first Tay-Sachs treatment to reach clinical trials.
Record-breaking technology can sequence an entire human genome in a matter of hours. The work could be a lifeline for people suffering from the more than 5,000 known rare genetic diseases.
A new agency and money for drugs for rare diseases are only very partial steps on the road towards what Canada really needs: a national pharmacare plan.
In 2030, there is a boom in precision medicine, where diseases – from cancer to dementia – are defined and targeted more specifically with a focus on their molecular makeup.
Specialty prescription drugs are responsible for countless medical miracles, but their high price tag is the main reason health care costs are out of control.
Children’s cancer is a rare disease, which means the market is small and pharmaceutical companies have few incentives to develop drugs for these cancers.